Avsnitt
-
Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.
-
Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.
-
Saknas det avsnitt?
-
Go online to PeerView.com/KNT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the basic biology of how the immune system responds to tumor activity, reviews the pathophysiology of the tumor microenvironment, provides up-to-date data supporting the use of cancer immunotherapies, including immune checkpoint inhibitors, and discusses investigational immuno-oncology pathways, putative targets for novel therapies, and current and emerging prognostic biomarkers to inform clinical treatment decisions. Upon completion of this activity, participants will be able to: Describe the foundational aspects of the immune system’s response to tumor activity through innate and adaptive immunity mechanisms, Review the pathophysiology of the tumor microenvironment and its relationship to tumor evasion and resistance, Characterize the mechanisms of action of the immune checkpoint inhibitors (ie, CTLA-4 and PD-1/PD-L1 inhibitors) and how they differ in their activity and adverse effects from conventional anticancer therapies, Summarize the current FDA-approved indications and investigational approaches with the immune checkpoint inhibitors across different tumors, Discuss investigational immuno-oncology pathways and potential new therapies that may be able to expand on the current therapies or overcome immune evasion and resistance, Assess current and emerging immuno-oncology biomarkers and their potential roles/uses, Integrate the latest immunotherapies and biomarker approaches into cancer care in the context of clinical practice or trials.
-
Go online to PeerView.com/BBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert discusses key concepts in oncology and supportive care biosimilars, including how they are defined, the regulatory approval process for these agents, and an overview of data for biosimilars in the treatment and supportive care of cancer patients. Upon completion of this activity, participants will be able to: Describe the biosimilar manufacturing process and differences between biosimilars and originator biologics used in the oncology setting, Discuss the concepts of biosimilar interchangeability, therapeutic equivalence, and safety in the context of the regulatory process, Cite efficacy evidence on the use of biosimilars in the management of solid tumors, including breast cancer, lung cancer, GI cancers, and others, Integrate biosimilars into oncology management plans in order to increase patient access to effective medications and improve health system efficiency.
-
Go online to PeerView.com/EQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium recently held in West Palm Beach, Florida, leading experts on multiple sclerosis (MS) dive into the latest data on approved and emerging therapies for relapsing and progressive forms of MS and offer practical strategies to improve patient management, treatment selection, and outcomes. In addition to exploring the treatment armamentarium for MS, the panel considers the prognostic and predictive utility of serum neurofilament light chain as an emerging biomarker, including how it may affect disease-modifying treatment selection and sequencing. Upon completion of this activity, participants should be better able to: Apply current data on approved and emerging disease-modifying therapies for the treatment of relapsing forms of MS, Employ recent data related to available and investigational therapies for the treatment of progressive forms of MS, Assess available data on the potential prognostic and predictive utility of serum neurofilament light chain levels in patients with MS, Develop strategies based on clinical phenotypes, goals, preferences, and potential biomarker findings when selecting disease-modifying therapies for patients with MS.
-
Go online to PeerView.com/NTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiology discusses best practices for the screening, diagnosis, and treatment of atrial fibrillation to reduce thromboembolic risk. Upon completion of this activity, participants will be able to: Recognize the prevalence of undiagnosed atrial fibrillation (AF) in patients 65 years and older at risk for AF and stroke, Discuss the need for opportunistic and systematic screening for AF among individuals 65 years of age and older and at high risk for AF and stroke, Employ various screening methods routinely in clinical practice to ensure that patients at risk for AF and stroke are diagnosed, Apply guideline recommendations as well as safety, efficacy, and real-world data on non–vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic risk reduction in patients with AF.
-
Go online to PeerView.com/GVC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses how to effectively diagnose and assess atopic dermatitis, common comorbidities, international treatment guidelines, and optimal treatment strategies, including phosphodiesterase-4 and interleukin-4/-13 inhibitors. Upon completion of this activity, participants should be better able to: Recognize the multidimensional burden and unmet needs associated with atopic dermatitis (AD), Employ evidence-based strategies to determine disease impact and guide treatment decisions in individual patients with AD, Assess clinical data on new and emerging treatment options for atopic dermatitis, Develop individualized treatment plans for adults, adolescents, and children with atopic dermatitis based on current recommendations, the safety and efficacy of new and emerging treatment options, comorbidities, and patient quality of life.
-
Go online to PeerView.com/MYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts on severe asthma discuss how to identify and diagnose patients with this condition and how novel treatments are improving patient outcomes. A patient joins the discussion to share his unique experience with severe asthma and how biologic therapy has improved his quality of life. Upon completion of this activity, participants should be better able to: Diagnose and evaluate patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapy, Employ evidence-based guidelines and the latest clinical data when selecting treatment for patients with severe asthma, Use strategies to communicate effectively with patients about self-management and to improve inhaler technique, adherence, and overall quality of life in patients with severe asthma.
-
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
-
Go online to PeerView.com/CBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist and certified diabetes educator discusses current and emerging treatment options for severe hypoglycemia. Upon completion of this activity, participants should be better able to: Recognize the role of glucagon for the treatment of severe hypoglycemia in patients with diabetes, Teach individuals outside of the hospital setting how and when to use glucagon to treat severe hypoglycemia, Evaluate the efficacy, safety, and ease of use of current and emerging glucagon rescue treatments for severe hypoglycemia
-
Go online to PeerView.com/UHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses the impact of dry eye disease and current and emerging treatment approaches for patients with dry eye disease. Upon completion of this activity, participants should be better able to: Recognize the impact of dry eye on the quality of life of patients, particularly if left untreated, Identify patients with dry eye according to signs, symptoms, and the latest diagnostic criteria, Summarize the latest clinical data on efficacy and safety of novel and emerging therapies for dry eye, Develop treatment plans for patients with dry eye according to disease severity and the latest clinical evidence of available therapeutic agents
-
Go online to PeerView.com/GZX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in hepatology discusses current and emerging strategies to diagnose, treat, and manage patients with nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Correctly diagnose and stage nonalcoholic fatty liver disease (NAFLD), distinguishing the subset of patients with NASH for disease monitoring and prognostication, Apply best practices in the management of patients with NASH based on evolving data on lifestyle modification and medical treatment, Evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, risks and benefits, and their potential utility in the treatment of patients with NASH
-
Go online to PeerView.com/QXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in medical genetics and inborn metabolism errors discusses novel strategies and emerging evidence for the identification and management of patients with long-chain fatty acid oxidation disorders. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms associated with the clinical presentation of long-chain fatty acid oxidation disorders (LC-FAOD), Review current recommendations for screening, diagnosis, and treatment of patients with LC-FAODs, Summarize the mechanism of action and emerging evidence for novel agents designed to address unmet needs among patients with LC-FAODs
-
Go online to PeerView.com/NNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hospital and vascular medicine discusses how real-world data enhance the data from randomized clinical trials on direct oral anticoagulants (DOACs) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) and offers insight on applying evidence from both real-world studies and randomized clinical trials to improve patient care. Upon completion of this activity, participants will be able to: Identify the role of real-world data and evidence in augmenting the efficacy and safety data that have been collected as part of clinical trials for stroke prevention among patients with NVAF, Compare and contrast evidence collected to date from real-world studies with data reported from clinical trials of DOACs to prevent stroke among patients with NVAF, Apply evidence from real-world studies and clinical trials of DOACs in patients with NVAF
-
Go online to PeerView.com/GZS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gastrointestinal oncology provides an update on targeted therapies for patients with biliary tract cancers. Upon completion of this activity, participants should be better able to: Review the rationale of newly discovered targets, such as multikinase tumor pathways, NTRK gene fusions, and FGFR translocations, for biliary tract cancers, Appraise emerging efficacy and safety evidence on the use of novel targeted agents, including multikinase, TRK, and FGFR inhibitors, in patients with biliary tract cancers, Incorporate novel targeted agents safely and effectively into treatment plans for biliary tract cancers, including in the context of a clinical trial
-
Go online to PeerView.com/UYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses new and late-breaking data on current and emerging treatments for multiple sclerosis from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019). Upon completion of this activity, participants should be better able to: Employ recently presented data related to approved disease-modifying therapies when treating patients with multiple sclerosis, Examine new data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Recognize the potential clinical utility of investigational disease-modifying therapies in the future management of multiple sclerosis
-
Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor
-
Go online to PeerView.com/SDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric neurology uses a novel, interactive talk to guide learners through the diagnosis and presymptomatic treatment of spinal muscular atrophy (SMA). Upon completion of this activity, participants should be better able to: Identify the important role of newborn screening in the presymptomatic treatment of spinal muscular atrophy, Cite available data on approved therapies for the treatment of spinal muscular atrophy, including presymptomatic patients, Apply approved therapies in presymptomatic patients with spinal muscular atrophy
-
Go online to PeerView.com/QWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious disease discusses strategies for increasing testing, diagnosis, and linkage to care in individuals who are at high risk for hepatitis C infection. Upon completion of this activity, participants should be better able to: Identify persons for whom HCV testing is recommended, Utilize appropriate diagnostic testing strategies for HCV, Incorporate national guidelines for HCV testing and diagnosis into routine clinical practice, Develop effective follow-up, counseling, and quality care strategies for patients with a confirmed diagnosis of HCV
-
Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP
- Visa fler